India's pharma exports cross $30B in FY25, record surge seen in March

In a remarkable milestone, India’s yearly drug and pharmaceutical exports reached an all-time high of $30 billion in Fiscal Year 2025, fueled by a 31 percent increase compared to the previous year in March.

Pharmaceutical exports in March increased by 31.21 percent year-over-year to $3681.51 million ($2805.71 million). The second-best performance during the fiscal year occurred in January, with exports increasing by 21.47 percent to $2590.88 million ($2132.92 million).

As per official trade statistics, pharmaceutical exports amounted to $30,467.32 million in FY25, which is over a 9 percent rise from $27,851.70 million in FY24.

According to a report by The Hindu, pharmaceutical exports reached $30 billion for the first time.

The value of exports to the US rose by 14.29 percent, reaching $8,953.37 million in FY25. Other nations alongside India's pharmaceutical exports included the UK, Brazil, France, and South Africa in the last fiscal year.

The performance in March was notable in a fiscal year that will be remembered for the events in the key US market, while India persisted in its attempts to leverage and expand on the initial successes from emerging markets. Initially, a shortage of generic prescription drugs in the US created optimism during the fiscal year, but as the year closed, the reciprocal 26 percent tariff that President Donald Trump proposed caused exporters to rush to send more. Pharma, however, was not included in the list of items for which the tax was declared and suspended for 90 days.